TORONTO, Oct. 31 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, announced today that Dr. Alan M. Ezrin, President and
Chief Executive Officer of the Company, will present at the Acumen BioFin
Rodman & Renshaw 9th Annual Healthcare Conference. Dr. Ezrin will provide an
update on the Company's preparations for the planned Phase III trial for
Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the
most common form of brain cancer. The conference is being held at the New York
Palace Hotel in New York City and Bradmer's presentation is scheduled for
Monday, November 5th at 9:10am ET in the Spellman Room.
